Cell Press

Cell Press is a leading publisher of biomedical research, renowned for its flagship title, Cell, and a portfolio of high-impact scientific journals. Founded in 1974, it has grown from a single journal into a major force in scientific communication, shaping discourse in fields like molecular biology, neuroscience, and immunology. Now a division of the global publishing giant Elsevier, it maintains editorial independence and a reputation for publishing groundbreaking research that often sets the agenda for the life sciences.

History

The origins of this publisher are inextricably linked to Benjamin Lewin, a molecular biologist who founded the journal Cell in 1974 while working at the Massachusetts Institute of Technology. The journal quickly gained prominence by focusing on mechanistic biology and maintaining rigorous editorial standards. In 1986, Lewin sold the enterprise to the Pergamon Press, which was later acquired by Elsevier in 1991. Under the stewardship of editors like Vivian Siegel and later Emilie Marcus, the portfolio expanded significantly, launching titles such as Neuron in 1988 and Immunity in 1994. This period of growth established its identity as a premier publisher of biomedical research, a status cemented by its relocation to Cambridge, Massachusetts, a hub for the biotechnology industry and academic institutions like Harvard University.

Publications

The publisher's portfolio is centered on a family of prestigious, discipline-specific journals, each aiming to be the premier title in its field. The flagship, Cell, covers the entire spectrum of the life sciences, while sister journals like Neuron, Immunity, and Cancer Cell provide focused outlets for top-tier research in their respective areas. Other notable titles include Current Biology, known for its broad biological scope and faster publication, Developmental Cell, and Cell Stem Cell. The portfolio also includes review journals such as Trends in Cell Biology and Molecular Cell, and has expanded into physical sciences with Chem and Joule. Each journal is known for its high impact factor and selective editorial process, often publishing work from leading institutions like the National Institutes of Health and Stanford University.

Scientific impact

The scientific impact of this publisher's journals is profound, as they frequently serve as the venue for landmark discoveries that redefine their fields. Seminal papers published in its titles have elucidated fundamental mechanisms in areas ranging from apoptosis and RNA interference to CRISPR gene editing and optogenetics. The publication of such high-profile research in journals like Cell and Neuron often garners significant attention from the broader scientific community and media outlets, influencing the direction of future research. This impact is reflected in consistently high citation metrics, and many articles become highly cited references, contributing to major advances recognized by awards like the Nobel Prize and the Lasker Award.

Business model and access

As part of Elsevier, the publisher operates primarily under a subscription-based business model, where institutions pay for access to its journal content. This model has been a focal point in the broader debate over open access in scientific publishing. In response, it has developed various open access options, including hybrid models where authors can pay an article processing charge to make their work freely available, and fully open access journals like Cell Reports and iScience. The content is hosted on the proprietary ScienceDirect platform, and the publisher also engages in initiatives like sharing accepted manuscripts after an embargo period to balance commercial interests with the demands of funders such as the Howard Hughes Medical Institute and Wellcome Trust.

Editorial policies and practices

Editorial decision-making is characterized by a rigorous pre-publication peer review process managed by teams of professional scientific editors, many with Ph.D.s and postdoctoral experience. These editors, rather than academic volunteers, make final acceptance decisions, aiming for rapid and authoritative judgments. The publisher has implemented policies to address issues of scientific integrity, including checks for image manipulation and adherence to standards for data sharing and clinical trial registration. It also emphasizes the importance of clear, accessible writing and visual presentation, with editorial staff working closely with authors to refine manuscripts. Furthermore, it has established clear guidelines on authorship and conflicts of interest to maintain the credibility of the research it publishes.

Category:Elsevier imprints Category:Scientific publishing companies of the United States Category:Companies based in Cambridge, Massachusetts Category:Academic publishing